Clinical outcome of salmon calcitonin nasal spray treatment in postmenopausal women after total hip arthroplasty

Gerontology

Volumn 51, Issue 4, 2005, Pages 242-252

  Peichl, P ^a   Griesmacher, A ^b   Kumpan, W ^c   Schedl, R ^e   Prosquil, E ^f   Broll H ^a,d  

^a Second Department of Internal Medicine with Rheumatology and Osteology   (Austria)

^b Institute of Physical Medicine and Rehabilitation   (Austria)

^c KAISER FRANZ JOSEF HOSPITAL   (Austria)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^e Hospital for Emergency Surgery   (Austria)

^f Department of Emergency Surgery SMZOst ^*  (Austria)

Author keywords

Activities of daily living; Aseptic loosening; Ca Vitd; Heterotopic ossification; Salmon calcitonin nasal spray; Total hip arthroplasty

Indexed keywords

CALCIUM; SALCATONIN; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EDEMA; FALLING; FEMALE; HEALTH STATUS; HIP FRACTURE; HUMAN; NOSE MUCOSA; OPEN STUDY; OSSIFICATION; PAIN; POSTMENOPAUSE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SYSTEMIC DISEASE; TOTAL HIP PROSTHESIS;

ADMINISTRATION, INTRANASAL; AGED; ARTHROPLASTY, REPLACEMENT, HIP; BONE DENSITY; BONE REMODELING; CALCINOSIS; CALCITONIN; FEMALE; HIP FRACTURES; HUMANS; OSTEOLYSIS; POSTMENOPAUSE; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; RECURRENCE; REOPERATION; TREATMENT OUTCOME;

EID: 20944438677     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085121     Document Type: Article

References (48)

1. Van der Lely AJ, Lamberts SW, Jauch KW, Swierstra BA, Hertlein H, Danielle De Vries D, Birkett MA, Bates PC, Blum WF, Attanasio AF: Use of human GH in elderly patients with accidental hip fracture. Eur J Endocrinol 2000;143:585-592.
2. Salkeld G, Cameron JD, Cumming RG, Easter S, Seymour J, Kurrie SE, Quine S: Quality of life related to fear of falling and hip fracture in older women: A time trade off study. BMJ 2000;320:341-346.
3. Seeman E: Selection of individuals for prevention of fractures due to bone fragility. Baillieres Best Pract Res Clin Endocrinol Metab 2000;14:233-249.
4. Lindsey R, Silvermann SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E: Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-323.
5. Haentjens P, Autier P, Barette M, Boonen S: The economic cost of hip factures among elderly women. A one-year, prospective, observational cohort study with matched-pair analysis. Belgian Hip Fracture Study Group. J Bone Joint Surg Am 2001;83:493-500
6. Hochberg M: Preventing fractures in post-menopausal women with osteoporosis. A review of recent controlled trials of antiresorptive agents. Drugs Aging 2000;17:317-330.
7. Kaufman JM: Role of calcium and vitamin D in the prevention and the treatment of post-menopausal osteoporosis: An overview. Clin Rheum 1995;14:9-13.
8. 3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637-1642.
9. Dambacher MA, Kranich M, Schacht E, Neff M: Can the fast bone loss in osteoporotic and osteopenic patients be stopped with active vitamin D metabolites? Calcif Tissue Int 1997;60:115-118.
10. Chapuy MC, Arlot M, Delmas PD, Meunier PJ: Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994;308:1081-1082.
11. Ebeling PR, Atley LM, Guthrie JR, Burger HG, Dennerstein L, Hopper JL, Wark JD: Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab 1996;81:3366-3371.
12. Laake K, Laake P, Ranhoff A H, Sveen U, Wyller TB, Bautz-Holter E: The Barthel ADL index: Factor structure depends upon the category of patient. Age Ageing 1995;24:393-397.
13. Raiche M, Hebert R, Prince F, Corriveau H: Screening older adults at risk of falling with the Tinetti balance scale. Lancet 2000;356:1001-1002.
14. Schneider P, Butz S, Allolio B, Börner W, Klein K, Lehmann R: Multicenter German reference data base for peripheral quantitative computer tomography. Technol Health Care 2000;369-373.
15. Zaninotto M, Bernardi D, Ujka F, Bonato P, Plebani M: A proposal for standardizing urine collections for bone resorption markers measurement. J Clin Lab Invest 1995;12:145-149.
16. DeLeo V, Ditto A, La Marca A, Lanzetta D, Massafra C, Morgante G: Bone mineral density and biochemical markers of bone turnover in peri- and postmenopausal women. Calcif Tissue Int 2000;66:263-267.
17. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C: Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Miner Res 1996;11:1531-1538.
18. Yu-Yahiro JA, Michael RH, Dublin NH, Fox KM, Sachs M, Hawkes WG, Hebel JR, Zimmerman SI, Shapiro J, Magaziner J: Serum and urine markers of bone metabolism during the year after hip fracture. J Am Geriatr Soc 2001;49:877-883.
19. Coyle D, Cranney A, Lee KM, Welch V, Tugwell P: Cost effectiveness of nasal calcitonin in postmenopausal women: Use of Cochrane collaboration methods for meta-analysis within economic evaluation. Pharmacoeconomics 2001;19:565-575.
20. Peichl P, Rintelen B, Kumpan W, Broll H: Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy. Gynecol Endocrinol 1999;13:7-14.
21. Peichl P, Griesmacher A, Pointinger P, Marteau R, Hartl W, Gruber W, Bröll H: Association between female sex hormones and biochemical markers of bone turnover in peri- and postmenopausal women. Calcif Tissue Int 1998;62:388-394.
22. Peichl P, Griesmacher A, Marteau R, Hejc S, Kumpan W, Müller MM, Bröll H: Serum crosslaps in comparison to serum osteocalcin and urinary bone resorption markers. Clin Biochem 2001;34:131-139.
23. Watts NB: Clinical utility of biochemical markers of bone remodeling. Clin Chem 1999;45:1359-1368.
24. Peichl P, Griesmacher A, Müller MM, Marteau R, Kumpan W, Bröll H: Serum osteocalcin and urinary crosslaps are suitable markers of bone turnover in response to short-term hormone replacement therapy. Gynecol Endocrinol 2000;14:374-381.
25. Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL: Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100-103.
26. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stephan J: The use of biochemical markers of bone turnover in osteoporosis. Osteoporosis Int Suppl 2000;6:S2-S17.
27. Lyritis GP, Ioannidis GV, Karachalios T, Roidis N, Kataxaki E, Papaioannou N, Kaloudis J, Galanos A: Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: A prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain 1999;15:284-289.
28. Levi SJ: Posthospital setting, resource utilization, and self-care outcome in older women with hip fracture. Arch Phys Med Rehabil 1997;78:973-979.
29. Hall SE, Williams JA, Senior JA, Goldswain PR, Criddle RA: Hip fracture outcome: Quality of life and functional status in older adults living in the community. Aust NZ J Med 2000;30:327-332.
30. LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J: Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 1999;281:1505-1511.
31. Takagi M, Santavirta S, Ida H, Ishii M, Takei I, Niissalo S, Ogino T, Konttinen YT: High-turnover periprosthetic bone remodeling and immature bone formation around loose cemented total hip joints. J Bone Miner Res 2001;16:79-88.
32. Delmas PD: The role of markers of bone turnover in the assessment of fracture risk in post-menopausal women. Osteoporos Int 1998;8 (suppl 1):S32-S6.
33. Antoniou J, Huk O, Zukor D, Eyre D, Alini M: Collagen cross-linked N-telopeptides as markers for evaluating particulate osteolysis: A preliminary study. J Orthop Res 2000;18:64-67.
34. Chapuriat RD, Garnero P, Breart G, Meunier PJ, Delmas PD: Serum type I collagen breakdown product (serum CTX) predicts hip fracture in elderly women: The EPIDOS study. Bone 2000;27:283-286.
35. Venesmaa PK, Kröger H, Miettinen H, Jurvelin J, Suomalainen O, Alhava E: Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: A prospective randomized study. J Bone Miner Res 2001;16:2126-2131.
36. Sabo D, Reiter A, Simank HG, Thomsen M, Lukoschek M, Ewerbeck V: Periprosthetic mineralization around cementless total hip endoprosthesis: Longitudinal study and crosssectional study on titanium threaded acetabular cup and cementless Spotorno stem with DEXA. Calcif Tissue Int 1998;62:177-182.
37. Hoikka V, Lindholm TS, Eskola A: Flurbiprofen inhibits heterotopic bone formation in total hip arthroplasty. Arch Orthop Trauma Surg 1990;109:224-226.
38. Thomas BJ, Amstutz HC: Prevention of heterotopic bone formation: Clinical experience with diphosphonates. Hip 1987;59-69.
39. Liebermann IH, Moran E, Hastings DE, Bogoch ER: Heterotopic ossification after primary cemented and noncemented total hip arthroplasty in patients with osteoarthritis and rheumatoid arthritis. Can J Surg 1994;37:135-139.
40. Tinetti ME, Baker DI, Gottschalk M, Garrett P, McGeary S, Pollack D, Charpentier P: Systematic home-based physical and functional therapy for older persons after hip fracture. Arch Phys Med Rehabil 1997;78:1237-1247.
41. Cumming RG, Salkeld G, Thomas M, Szonyi G: Prospective study of the impact of fear of falling on activities of daily living, SF-36 scores, and nursing home admission. J Gerontol A Biol Sci Med Sci 2000;55:299-305.
42. Hopman-Rock M, Odding E, Hofmann A, Kraaimaat F W, Bijlsma JWJ: Physical and psychosocial disability in elderly subjects in relation to pain in the hip and/or knee. J Rheumatol 1996;23:1037-1044.
43. Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-276.
44. Gennari C, Agnusdei D, Montagnani M, Gonnelli S, Civitelli R: An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tiss Int 1992;50:381-383.
45. Gennari C, Agnusdei D, Cepollaro C: Effect on bone mass and bone turnover of a 2-year intermittent or continuous treatment with salmon calcitonin nasal spray in postmenopausal osteoporotic patients. Proc 11th International Conference on Calcium-Regulating Hormones, 1992, vol 11, pp 400-406.
46. Overgaard K, Christiansen C: A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin. Calcif Tissue Int 1996;59:12-16.
47. Overgaard K: Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response study. Calcif Tissue Int 1994;55:82-86.
48. Thamsborg G, Jensen JE, Kollerup G, Hauge EM, Melsen F, Sorensen OH: Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. Bone 1996;18:207-212.